Background and aims: Injection of botulinum toxin (BT) from direct vision into the lower esophageal sphincter (LES) lowers its basal tone and improves symptomatology in most of the patients with achalasia. We hypothesized that the effect could be improved by better degree of LES infiltration by toxin administered from both prograde and retrograde views. The aim of the study was to investigate the feasibility, safety and efficacy of this modified method of intrasphincteric BT injection in patients with achalasia.
Patients and method: Sixteen patients with achalasia were treated with BT injection. Hundred units of BT (Botox®) were diluted with 4 ml of normal saline. Aliquots of 0.5 ml were injected into four quadrants of the LES from retrovision and then into each quadrant from direct vision. The patients were followed up for a median of 25.5 months (range 19 - 31).
Results: No serious adverse events were noted. All patients responded well to the injection within one week and 3 patients (18.7 %) experienced an early relapse. The remaining 13 patients were classified as responders. After a single BT injection, 11 responders reported a relapse and 2 patients remained asymptomatic. The median symptom-free interval was 17 months (8 - 28). Five patients with a relapse underwent BT reinjection. Three of them remained asymptomatic and two experienced the second relapse. After BT reinjection, the median symptom-free interval was 16 months (10 - 19). All other patients with a relapse and without BT reinjection were treated with either balloon dilatation or surgery and are currently asymptomatic
Conclusion: Combining injection of BT into the LES from both direct vision and retrovision was feasible, safe and produced a rapid response which was sustained for more than 1 year in the majority of patients. This method of BT administration might be superior to the traditional injection from direct view only, and a randomized and prospective study comparing those techniques of administration should be performed.
References
-
1
Pasricha P J, Ravich W J, Kalloo A N.
Botulinum toxin for achalasia.
Lancet.
1993;
341
244-245
-
2
Pasricha P J, Kalloo A N.
Recent advances in the treatment of achalasia.
Gastrointest Endosc Clin N Am.
1997;
7
191-206
-
3
Pasricha P J, Ravich W J, Hendrix T R. et al .
Intrasphincteric botulinum toxin for the treatment of achalasia.
N Engl J Med.
1995;
322
774-778
-
4
Pasricha P J, Rai R, Ravich W J. et al .
Botulinum toxin for achalasia: long-term outcome and predictors of response.
Gastroenterology.
1996;
110
1410-1415
-
5
Annese V, Bassoti G, Coccia G. et al .
A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group.
Gut.
2000;
46
597-600
-
6
Annese V, Bassoti G, Coccia G. et al .
Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group.
Aliment Pharmacol Ther.
1999;
13
1347-1350
-
7
Muehldorfer S M, Schneider T H, Hochberger J. et al .
Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilatation.
Endoscopy.
1999;
31
517-521
-
8
Ghoshal U C, Chadhuri S, Pal B B. et al .
Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia.
Dis Esophagus.
2001;
14
227-231
-
9
Annese V, Basciani M, Perri F. et al .
Controlled trial of botulinum toxin injection versus placebo and pneumatic dilatation in achalasia.
Gastroenterology.
1996;
111
1418-1424
-
10
Mariorana A, Fiorentino E, Genova E G. et al .
Echo-guided injection of botulinum toxin in patients with achalasia: initial experience.
Endoscopy.
1999;
31
3-4
-
11
Goldstein J A, Barkin J S.
Botox injection for achalasia: a modified technique.
Gastrointest Endosc.
1999;
49
272-273
J. Martínek, M. D.
Institute for Clinical and Experimental Medicine, Dept. of Hepatogastroenterology ·
Vídeňská 1958/9 · 140 21 Praha 4 · Czech Republic
Fax: + 420-2-6136-2615 ·
Email: jan.martinek@medicon.cz
